Point72 DIFC Ltd Has $806,000 Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Point72 DIFC Ltd grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 443.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,517 shares of the biopharmaceutical company's stock after purchasing an additional 11,848 shares during the quarter. Point72 DIFC Ltd's holdings in Ultragenyx Pharmaceutical were worth $806,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Algert Global LLC lifted its stake in Ultragenyx Pharmaceutical by 46.9% during the third quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company's stock worth $4,105,000 after purchasing an additional 23,580 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $17,468,000. Candriam S.C.A. boosted its holdings in shares of Ultragenyx Pharmaceutical by 33.1% in the 2nd quarter. Candriam S.C.A. now owns 688,942 shares of the biopharmaceutical company's stock valued at $28,314,000 after buying an additional 171,345 shares during the period. Bamco Inc. NY bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $2,666,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Ultragenyx Pharmaceutical by 47.9% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 73,289 shares of the biopharmaceutical company's stock worth $3,012,000 after acquiring an additional 23,752 shares during the period. Institutional investors own 97.67% of the company's stock.

Analysts Set New Price Targets

RARE has been the subject of a number of research reports. Royal Bank of Canada restated an "outperform" rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Cantor Fitzgerald restated an "overweight" rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. HC Wainwright upped their price objective on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th. TD Cowen raised their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $87.46.

Ultragenyx Pharmaceutical Stock Up 4.3 %

Ultragenyx Pharmaceutical stock traded up $2.04 during trading hours on Friday, hitting $49.38. 815,449 shares of the company traded hands, compared to its average volume of 774,882. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The firm has a market cap of $4.56 billion, a P/E ratio of -7.63 and a beta of 0.56. The firm's 50-day simple moving average is $51.17 and its two-hundred day simple moving average is $48.82.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts' consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business's revenue for the quarter was up 42.3% on a year-over-year basis. During the same quarter last year, the business earned ($2.23) earnings per share. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the transaction, the chief financial officer now owns 92,301 shares in the company, valued at approximately $4,869,800.76. The trade was a 7.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.80% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.